Up Date on Non-Alcoholic Fatty Liver Disease and Fibrosis
Article Sidebar
Main Article Content
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
Chalasani NP. Nonalcoholic steatohepatitis. In: Chalasani NP, et al, editors. Annual Board review and update in Gastroenterology. Post graduate course 2004. October 30. Florida. p.227-36.
Bacon BR, Farahvash MJ, Janney CG, NeuschwanderTetri BA. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 1994; 107: 1103-9.
Kodali VP, Gordon SC, Silveman AL, et al. Cryplogenic liver disease in the Linited States: Further evidence for non-A, non-B, and non-Chepatitis. Am J Gastroenterol 1994; 89:1836-9.
Browning JD, Kumar KS, Saboorian MIH, et al. Ethnic differences in the prevalence of cryptogenic cirrhosis. Am J Gastroenterol 2004; 99: 292-8.
Kladchareon N, Treeprasertsuk S, Mahachai V, Wilaiaratana P, Kullavanijaya P. The Prevalence of Nonalcoholic Steatohepatitis in Thai Patients with Non HBV, Non-HCV Chronic Hepatitis. J Med Assoc Thai 2004; 87(Suppl 2): S29-S54.
Ong J, Younossi ZM, Reddy V, et al. Cryptogenic cirrhosis and post-transplantation nonalcoholic fatty liver disease. Liver Transpl 2001; 7: 797-801.
Poonawala A, Nair SP, Thuluvath PJ Prevalence of obesity and diabetes in patients with cryptogenic cirhosis: A case-control study. Hepatology 2000; 32: 689-92.
Caldwell SH, Oelsner DH, Iezzoni JC, et al. Cryptogenic cirrhosis: Clinical characterization and risk factors for underlying disease. Hepatology 19999; 29: 664-9.
Angulo P, Keach JC, Batts KP, et al. Indepent predictors of liver fibrosis in patients with nonalcobolic steatohepatitis. Hepatology 1999; 30: 1356-62.
Ratziu V. Giral P. Charlotte F. et al. Liver fibrosis in overweight patients. Gastroenterology 2000; 118: 1117-23.
Powell EE, Cooksley WG, Hanson R, et al. The natural history of nonalcoholic steatohepatitis: A follow-up study of forty-two patients for up to 21 years. Hepatology 1990; 11:74-80.
Ratziu V, Bonyhay L, Di Martino V,etal. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology 2002; 35: 1485-93.
Castillo I,Pardo M, Bartolome J, et al. Occult hepatitis C virus infection in patients in whom the etiology of persistently abnormal results of liver-function tests unknown. J Infect Dis 2004; 189: 7-14.
Bugianesi E, Leone N, Vanni E, et al. Expanding the natural history of nonalcoholic steatohepatitis: From oryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002; 123: 134-40.
Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel IIII) final report. Circulation 2002; 106: 3143-421.
Havel PJ. Update on adipocyte hormones: regulation of energy balance and carbohydrate lipid metabolism. Diabetes 2004; 53(Suppl 1): S143-S151.
Bajaj M, Suraamomkul S, Piper P, etal. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in piogitazonetreated type 2 diabetic patients. I Clin Endocrinol Metab 2004; 89: 200-6.
Lopez-Bermejo A, Botas P, Funahashi T, et Adiponce-
tin, hepatocellular dysfunction and insulin sensitivity. Clin Endocrinol 2004 ; 60: 256-63.
Yokoyama H, Hirose H. Ohgo H, Saito ito I Inverse association between serum adiponcetin level and transaminase activities in Japanese male workers. J Hepatol 2004; 41:19-24.
Xu A. Wang Y, Keshaw H. Xu LY, Lam KS, Cooper
GJ. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 2003; 112:91-100.
Yagmur M, Trautwein C, Gressner AM, Tacke F. Resistin Serum Levels are Associated with Insulin Resistance, Disease Severity, Clinical Complications, and Prosis in Patients with Chronic Liver Diseases. Am J Gastroenterol 2006; 101: 1244-52.
Hui JM, Hodge A. Farrell GC, et al. Beyond insulin resistance in NASH: TNF-? or adiponectin?. Hepatology 2004; 40:46-54.
Brunt EM, Janney CG, Di Bisceglie AM, et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 2467-74.
Matteoni CA, Younossi ZM, Gramlich T, et al. Nonalcoholic fatty liver discase: a specctrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413-9.
Castera L, Vergniol J, Foucher J, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128: 343-50.
Halfon P, Imbert-Bismut F, Messous D, et. A prospective assessment of the inter-laboratory variability ofbiochemical markers of fibrosis (Fibro Test) and activity (ActiTest) in patients with chronic liver disease. Comp Hepatol 2002; 1:3.
Poynard T, Imbert-Bismut F, Munteanu M. et al. Overview of the diagnostic value of biochemical markers of liver fibrosis (Fibro Test, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatis Comp Hepatol 2004; 3: 8.
Ninomiya T. Yoon S, Hayashi Y, etal. Clinical signifi- cance of serum hyaluronic acid as a fibrosis marker in chronic hepatitis C patients treated with interferon alpha: histological evaluation by a modified histological activity index scoring system. J Gastroenterol Hepatol 1998; 13: 68-74.
Rosenberg WM. Voelker M. Thiel R. etal. Serum mar- kers detect the presence of liver fibrosis; a cohort shudy. Gastroenterology 2004; 127: 1704-13.
Poynard T, Ratziu V, Naveau S, et al. Diagnostic value of two new biomarkers (Steatotest and nashtest) for the prediction of steatosis and non-alcoholic steato-hepatis (NASH). I Hepatology 2006; 44 (Suppl 2): S38 [Abstract)
de Ledinghen V, Beaugrand M, Keileher TB, et al. Prediction of liver fibrosis in non-alcoholic steato-hepatitis (NASH): Risk factors and diagnostic potential of liver elasticity using fibroscan. J Hepatology 2006; 44 (Suppl 2): S87. [Abstract]
Ratziu V, Giral P, Charlotte F, et al. Liver fibrosis in overweight patients. Gastroenterology 2000; 18:1117-23.
Palmer M, Schaffiner F. Effect of weight reduction on hepatic abnormalities in overweight patients Gastroenterology 1990; 99: 1408-13.
Andersen T, Gluud C, Franzmann MB, et al. Hepatic effects of dietary weight loss in morbidly obese subjects. J Hepatol 1991; 12: 224-29.
Ueno T, Sugawara H, Sujaku K, etal. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol 1997; 27: 103-7.
Sjostrom L, Lindroos AK, Peltonen M, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004; 351: 2683-93.
Dixon JB, Bhathal PS, Hughes NR, et al. Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss. Hepatology 2004; 39: 1647-54.
Marchesini G, Brizi M, Bianchi G, et al. Metformin in non-alcoholic steatohepatitis. Lancet 2001; 358: 893~4.
Nair S, Diehl AM, Wiseman M, et al. Metformin in the treatment of non-alcoholic steatohepatis: a pilot open label trial. Aliment Pharmacol Ther 2004; 20: 23-8.
Caldwell SH, Hespenheide EE, Redick JA, et al. A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am J Gastroenterol 2001;96: 519-25.
Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, et al. Improved nonalcobolic stcatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 2003; 38: 1008-17.
Promrat K, Lutchman G, Uwarfo Gl, et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 2004; 39: 188-96.
Laurin J, Lindor K, Crippin I, et al. Ursodeoxycholic acid or clofibrate in the treatment of nonalcohol -induced steatohepatitis: a pilot study. Hepatology 1996;23: 1464-7.
Basaranoglu M, Acbay O, Sonsuz A. A controlled trial of gemfibrozzil in the treatment of patients with nonalcoholic steatohepatitis. J Hepatol 1999; 31: 384.
Kivici M, Gulten M, Gurel S, et al. Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis. Can J Gastroenterol 2003; 17: 713-8.
Harrison SA, Fincke C, Helinski D, et al. A pilot study of orlistat treatment in obese, non-alcoholic steatohepatitis patients. Aliment Pharmacol Ther 2004; 20: 623-8.
Lavine JE, Vitamin E treatment of nonalcoholic steatohe- patitis in children: a pilot study. I Podiatr 2000: 734-8.
Harrison SA, Torgerson S, Hayashi P, et al. Vitamin Eand vitamin C treatment improves fibrosis in patients
with nonalcoholic steatohepatitis. Am J Gastroenterol 2003;98:2485-90.
Abdelmalek MF, Angulo P, Jorgensen RA, et al. Betaine, a promising new agent for patients with nonalcoholic
steatohepatitis: results of a pilot study. Am I Gastroenterol 2001; 96: 2711-7.
Gulbahar O, Karasu Z, Ersoz G, et al Treatment of nonalcoholic steatohepatitis with N-acetylcysteine. Gastro- enterology 2000; 118: A 1444.
Satapathy SK, Garg S, Chauhan R, et al. Bencficial effects of tumor necrosis factor-alpha inhibition by pentoxi- fylline on clinical, biochemical, and metabolic parameters of patients with nonalcoholic steatohepatis. Am I Gastro~ enterol 2004; 99: 1946-52